Royal Bank Of Canada set a $19.00 price target on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report published on Monday. The brokerage currently has a sector perform rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on the stock. Guggenheim assumed coverage on shares of Valeant Pharmaceuticals International in a report on Saturday. They issued a buy rating and a $18.00 price target for the company. BidaskClub cut shares of Valeant Pharmaceuticals International from a hold rating to a sell rating in a report on Friday. Cantor Fitzgerald assumed coverage on shares of Valeant Pharmaceuticals International in a report on Friday. They issued an overweight rating and a $18.00 price target for the company. Wells Fargo & Co reaffirmed an underperform rating on shares of Valeant Pharmaceuticals International in a report on Monday, June 12th. Finally, BMO Capital Markets reaffirmed a market perform rating and issued a $15.00 price target on shares of Valeant Pharmaceuticals International in a report on Friday, June 9th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $16.26.

Shares of Valeant Pharmaceuticals International (VRX) traded down 1.34% during midday trading on Monday, hitting $13.29. 8,671,948 shares of the company traded hands. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $32.74. The stock’s market capitalization is $4.62 billion. The company has a 50-day moving average price of $12.38 and a 200-day moving average price of $12.92.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $1.93. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business’s quarterly revenue was down 11.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.08) earnings per share. Analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

WARNING: This story was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/06/20/valeant-pharmaceuticals-international-inc-vrx-given-a-19-00-price-target-by-royal-bank-of-canada-analysts.html.

In related news, Director Schutter Richard U. De acquired 20,000 shares of the firm’s stock in a transaction on Thursday, May 11th. The shares were acquired at an average cost of $13.90 per share, with a total value of $278,000.00. Following the completion of the acquisition, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 5.87% of the company’s stock.

A number of institutional investors have recently bought and sold shares of VRX. Gruss & Co. Inc. bought a new position in Valeant Pharmaceuticals International during the first quarter valued at about $104,000. Financial Architects Inc increased its position in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the last quarter. Harbor Advisors LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at about $110,000. WMS Partners LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at about $116,000. Finally, Brave Asset Management Inc. bought a new position in Valeant Pharmaceuticals International during the first quarter valued at about $119,000. 50.45% of the stock is currently owned by institutional investors and hedge funds.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.